- Market Size (2026)
- USD 5.8 Bn
- Forecast (2036)
- USD 15.1 Bn
- CAGR (2026 to 2036)
- 10.0%
Point-of-care Molecular Diagnostics Market Size, Market Forecast and Outlook By FMI
The point-of-care molecular diagnostics market was valued at USD 5.3 billion in 2025. The market is set to reach USD 5.8 billion by 2026-end and grow at a CAGR of 10.0% between 2026-2036 to reach USD 15.1 billion by 2036. Assays and Kits will dominate with a 52.7% share, while Real Time Polymerase Chain Reaction will lead with a 64.2% share.
Point-of-care Molecular Diagnostics Market Overview: Size and Forecast
| Metric | Value |
|---|---|
| Market Size (2026) | USD 5.8 Billion |
| Market Size (2036) | USD 15.1 Billion |
| CAGR (2026–2036) | 10.0% |
| Leading Product Type | Point-Of-Care Molecular Diagnostics Market |
| Point-Of-Care Molecular Diagnostics Market Share | 52.7% |
| Key Growth Markets | USA, UK, Japan, South Korea |
| Key Players | Point-of-care Molecular Diagnostics Market Key Players: Abbott Laboratories, Cepheid (Danaher Corporation), bioMérieux SA, Roche Diagnostics, QuidelOrtho Corporation |
| Parameter | Details |
|---|---|
| Market Size in 2026 (Value) | USD 5.8 Bn |
| Market Forecast in 2036 (Value) | USD 15.1 Bn |
| CAGR (2026 to 2036) | 10.0% |
| Years Considered | 2021 to 2036 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2036 |
| Units Considered | Value (USD Bn) |
| Leading Sub-Region | Japan |
Summary of the Point-of-care Molecular Diagnostics Market
- Demand and Growth Drivers
- Respiratory Diseases, and Sexually Transmitted Diseases applications are expected to sustain procurement of assays and kits products as clinical protocols tighten and patient populations expand through 2036.
- Real Time Polymerase Chain Reaction and isothermal nucleic acid amplification are projected to shape procurement patterns, with regulatory-approved formats capturing the largest volume share.
- Japan at 10.3% and USA at 10.2% are the fastest-growing markets, reflecting expanding institutional infrastructure and policy-driven adoption during the forecast period.
- Product and Segment View
- Real Time Polymerase Chain Reaction is expected to account for 64.2% of the technology segment in 2026, supported by demand across Respiratory Disease Assays, Influenza Testing Kits, and Coronavirus Detection Kits in clinical and diagnostic settings.
- Cancer and Oncology Assays is projected to gain share during the forecast period as genetic mutation detection and tumor marker panels applications expand across Respiratory Diseases, and Sexually Transmitted Diseases sectors.
- By technology, Real Time Polymerase Chain Reaction at 64.2% leads demand, reflecting a preference over isothermal nucleic acid amplification and other technologies across end-use buyers.
- Geography and Competitive Outlook
- Japan is projected to lead growth at 10.3% through 2036, driven by PMDA approval pathways, aging population demographics, and hospital automation investment supporting assays and kits demand.
- USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita assays and kits utilization rates in hospital and ambulatory settings.
- Abbott Laboratories and Cepheid (Danaher Corporation) lead the competitive field through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts across high-volume markets.
- Analyst Opinion
- Sabyasachi Ghosh, Principal Consultant at FMI says, 'Companies that can align real time polymerase chain reaction product portfolios with evolving respiratory diseases requirements while maintaining cost-competitive pricing across cancer and oncology assays categories are expected to strengthen their procurement positions through the forecast period.'
- The point-of-care molecular diagnostics market is shifting from a standardized supply model toward differentiated product portfolios where assays and kits performance, real time polymerase chain reaction capability, and total cost of ownership shape purchasing decisions.
- Adoption is increasing due to respiratory diseases and sexually transmitted diseases demand, regulatory protocol updates, and replacement of legacy software and services configurations that no longer meet current requirements.
- Demand is further supported by procurement consolidation among physicians offices buyers and preference for suppliers combining assays and kits breadth with real time polymerase chain reaction capability.
Point-of-care Molecular Diagnostics Market Definition
The point-of-care molecular diagnostics market encompasses medical devices, consumables, and services used across Respiratory Diseases, Sexually Transmitted Diseases, and Hospital Acquired Infections applications, serving Physicians Offices, and Hospitals and Intensive Care Units sectors.
Point-of-care Molecular Diagnostics Market Inclusions
Market scope encompasses all commercially traded point-of-care molecular diagnostics products categorized by product (Assays and Kits, Cancer and Oncology Assays, Instruments and Analyzers, and others), technology (Real Time Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, and Other Technologies), application (Respiratory Diseases, Sexually Transmitted Diseases, Hospital Acquired Infections, and others), end use (Physicians Offices, Hospitals and Intensive Care Units, Research Institutes, and others), sample type (Blood Samples, Swab Samples, and Urine Samples), deployment (Portable Systems, and Near Patient Systems). Revenue estimates cover the period from 2026 to 2036 across all regions and distribution channels.
Point-of-care Molecular Diagnostics Market Exclusions
The scope does not include unregulated or non-commercial medical products, experimental devices without regulatory clearance, or services unrelated to point-of-care molecular diagnostics procurement and clinical deployment.
Point-of-care Molecular Diagnostics Market Research Methodology
- Primary Research: FMI analysts conducted interviews with device manufacturers, clinical procurement specialists, hospital supply chain managers, and end-use operators across Japan, USA, and EU to validate demand patterns and pricing structures for assays and kits and related product categories.
- Desk Research: Combined clinical trial registries, regulatory approval databases, reimbursement data, and manufacturer disclosures to establish baseline parameters for point-of-care molecular diagnostics across product and technology segments.
- Market Sizing and Forecasting: Bottom-up aggregation across Assays and Kits, Cancer and Oncology Assays, and Instruments and Analyzers product categories and Respiratory Diseases, Sexually Transmitted Diseases, and Hospital Acquired Infections applications, triangulated with top-down macro indicators and regional adoption curves.
- Data Validation: Quarterly data are cross-validated with regulatory clearance volumes, hospital procurement records and manufacturer revenue disclosures for point-of-care molecular diagnostics products.
Why is the Point-of-care Molecular Diagnostics Market Growing?
- Sustained procurement is being created for assays and kits for Respiratory Diseases, and Sexually Transmitted Diseases applications and for cancer and oncology assays products across both established and emerging markets.
- Japan is driving growth at 10.3% driven by PMDA approval pathways, aging population demographics and hospital automation investment supporting demand for assays and kits.
- In the technology segment, Real Time Polymerase Chain Reaction (RT-PCR) holds a share of 64.2% and is supported by the need for Respiratory Disease Assays, Influenza Testing Kits configurations, and wide applicability in clinical settings.
The point-of-care molecular diagnostics market is expected to be worth USD 5.8 Bn in 2026 and is expected to reach USD 15.1 Bn by 2036, growing at a CAGR of 10.0%. The growth is attributed to the increasing demand for Assays and Kits and Cancer and Oncology Assays in applications such as Respiratory Diseases, Sexually Transmitted Diseases, and Hospital Acquired Infections. The USD 9.3 Bn incremental opportunity from 2026 to 2036 speaks to the cumulative impact of clinical adoption, regulatory compliance cycles and geographic expansion of procurement. Processing is mainly done by Real Time Polymerase Chain Reaction . Isothermal nucleic acid amplification is gaining popularity in certain applications .
In the technology segment, Real Time Polymerase Chain Reaction is leading with 64.2% in 2026. The demand is aimed at sub-categories Respiratory Disease Assays, Influenza Testing Kits and Coronavirus Detection Kits, each targeting different respiratory diseases needs. Cancer and Oncology Assays is viewed as a secondary growth category with the sub-segments of Genetic Mutation Detection and Tumor Marker Panels gaining traction as procurement diversifies.
From a geographical perspective, Japan dominates with 10.3% owing to the PMDA approval pathways, aging population demographics, and hospital automation investment fueling demand for assays and kits. USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures and high per-capita assay and kits utilization rates in hospital and ambulatory settings. Demand in North America and Western Europe is driven by replacement and compliance cycles.
Market Segmentation Analysis
- In the technology segment, Real Time Polymerase Chain Reaction is dominating with a 64.2% share in 2026, with Respiratory Disease Assays and Influenza Testing Kits accounting for the majority of procurement volume across clinical channels.
- Technology reflects existing procurement patterns across real time polymerase chain reaction and isothermal nucleic acid amplification, Real Time Polymerase Chain Reaction at 64.2%.
- Application segmentation reveals respiratory diseases to be the top channel, reflective of institutional procurement structures and GPO relationships in high volume markets.
The point of care molecular diagnostics market is segmented based on product, technology, application, end use, sample type, and deployment. The market is segmented on the basis of product into Assays and Kits, Cancer and Oncology Assays, Instruments and Analyzers, and Software and Services. Each of these segments has specific procurement requirements. The major segments are: technologies (Real Time Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification and Other Technologies).
Insights into the Assays and Kits Segment
The product segment is dominated by Assays and Kits with 52.7% in 2026 indicating focused demand across hospital, diagnostic and outpatient settings. These include Respiratory Disease Assays, Influenza Testing Kits, Coronavirus Detection Kits and Sexually Transmitted Disease Assays. These sub-categories cover differentiated respiratory diseases needs and procurement specifications.
Assays and kits are purchased based on alignment with clinical protocols, regulatory clearance, and institutional formulary. The respiratory disease assays sub-category is leading in terms of volume, while the influenza testing kits is gaining share with expansion of sexually transmitted diseases applications.
Insights into the Cancer and Oncology Assays Segment
Cancer and Oncology Assays is in the growth category of the product segment. Sub categories include Genetic Mutation Detection and Tumor Marker Panels for specialized requirements in a range of applications like Respiratory Diseases and Sexually Transmitted Diseases.
Growing adoption of cancer and oncology assays fuelled by evolving clinical protocols, updated regulatory requirements and growing demand for precision grade products in sexually transmitted diseases settings. The major sub-categories of growth during the forecast period are Genetic Mutation Detection and tumor marker panels.
Point-of-care Molecular Diagnostics Market Drivers, Restraints, and Opportunities
- Respiratory Diseases and sexually transmitted diseases applications are the primary structural drivers, creating recurring procurement cycles for assays and kits products through 2036.
- Reimbursement constraints, pricing pressure in institutional procurement, and lengthy regulatory approval timelines represent the main restraints limiting adoption in price-sensitive market segments.
- Point-of-care expansion, emerging market hospital modernization, and clinical protocol updates are expected to create incremental procurement opportunities through the forecast period.
The point-of-care molecular diagnostics market is supported by structural demand from Respiratory Diseases, and Sexually Transmitted Diseases applications. Real Time Polymerase Chain Reaction remains the dominant processing approach, while isothermal nucleic acid amplification gains traction in specialized applications. Restraints include regulatory compliance costs and pricing pressure.
Respiratory Diseases Demand and Regulatory Procurement Cycles for Assays and Kits
Application requirements especially in respiratory diseases and sexually transmitted diseases are resulting in recurring procurement cycles for assays and kits. The Respiratory Disease Assays and influenza testing kits sub-categories account for the majority of volume. The specifications are driven by physicians offices operator requirements and real time polymerase chain reaction compatibility. Growth is fueled by new adoption in new markets and replacement of legacy products in mature regions.
Pricing Pressure and Reimbursement Constraints on Cancer and Oncology Assays Adoption
Cancer and oncology assays are, however, subject to institutional pricing pressure, reimbursement constraints in emerging markets, and long regulatory approval cycles that delay the time-to-market for new configurations. Hospital procurement committees favor products with proven cost effectiveness over a defined clinical use cycle, which creates barriers for new entrants that lack established reimbursement codes.
Emerging Market Expansion and Assays and Kits Procurement Growth in Japan
Growth is led by Japan at 10.3% due to PMDA approval pathways, aging population demographics and hospital automation investment supporting assays and kits demand. USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures and high per-capita assays and kits utilization rates in hospital and ambulatory settings. These markets are expected to be the major growth corridors for assays and kits procurement through 2036. Demand in respiratory diseases and sexually transmitted diseases applications.
Analysis of Point-of-care Molecular Diagnostics Market By Key Countries
.webp "Top Country Growth Comparison Point Of Care Molecular Diagnostics Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| Japan | 10.3% |
| USA | 10.2% |
| EU | 10.1% |
| South Korea | 10.0% |
| UK | 9.8% |
- Japan at 10.3% reflects PMDA approval pathways, aging population demographics, and hospital automation investment supporting assays and kits demand.
- USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita assays and kits utilization rates in hospital and ambulatory settings.
- EU at 10.1% reflects EU MDR regulatory transition, hospital modernization across member states, and centralized procurement structures for assays and kits products.
The global point-of-care molecular diagnostics market is projected to expand at 10.0% from 2026 to 2036. The study covers more than 30 countries, and the primary markets are listed below.
Demand Outlook for Point-of-care Molecular Diagnostics Market in Japan
Demand for point-of-care molecular diagnostics in Japan is concentrated in respiratory diseases and sexually transmitted diseases applications, with the market projected to grow at 10.3% through 2036. Growth is attributable to PMDA approval pathways, aging population demographics, and hospital automation investment supporting assays and kits demand.
- Procurement of assays and kits is concentrated in hospital and clinic channels, reflecting respiratory diseases requirements and regulatory compliance standards in Japan.
- Adoption of cancer and oncology assays is expanding across diagnostic and outpatient settings as clinical protocols evolve and physicians offices buyers expand supplier qualification programs.
- Real time polymerase chain reaction demand reflects clinical validation requirements and growing preference for regulatory-cleared assays and kits products with verified efficacy and safety data.
Future Outlook for Point-of-care Molecular Diagnostics Market in USA
Government and regulatory frameworks in USA are creating structured procurement demand for assays and kits, with the market expanding at 10.2% through 2036. Demand reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita assays and kits utilization rates in hospital and ambulatory settings.
- Respiratory diseases applications are generating volume for hospital and clinic channels, reflecting respiratory diseases requirements and regulatory compliance standards in USA.
- Cancer and oncology assays procurement is supported by diagnostic and outpatient settings as clinical protocols evolve and physicians offices buyers expand supplier qualification programs.
- Sexually transmitted diseases demand is creating incremental opportunities for clinical validation requirements and growing preference for regulatory-cleared assays and kits products with verified efficacy and safety data.
Opportunity Analysis of Point-of-care Molecular Diagnostics Market in EU
EU's healthcare infrastructure and institutional procurement base supports a growth rate of 10.1% through 2036 for point-of-care molecular diagnostics products. Procurement patterns reflect EU MDR regulatory transition, hospital modernization across member states, and centralized procurement structures for assays and kits products.
- Assays and kits demand is shaped by hospital and clinic channels, reflecting respiratory diseases requirements and regulatory compliance standards in EU.
- Investment in respiratory diseases is driving procurement of diagnostic and outpatient settings as clinical protocols evolve and physicians offices buyers expand supplier qualification programs.
- Replacement cycles for legacy cancer and oncology assays configurations are supporting clinical validation requirements and growing preference for regulatory-cleared assays and kits products with verified efficacy and safety data.
In-depth Analysis of Point-of-care Molecular Diagnostics Market in South Korea
Regulatory requirements in South Korea are shaping assays and kits procurement standards, with the market growing at 10.0% through 2036. Demand drivers include MFDS regulatory frameworks, advanced hospital infrastructure, and domestic medical device OEM positions supporting assays and kits adoption.
- Institutional procurement of assays and kits reflects hospital and clinic channels, reflecting respiratory diseases requirements and regulatory compliance standards in South Korea.
- Sexually transmitted diseases applications are accelerating adoption of diagnostic and outpatient settings as clinical protocols evolve and physicians offices buyers expand supplier qualification programs.
- Supply chain development for cancer and oncology assays is expanding clinical validation requirements and growing preference for regulatory-cleared assays and kits products with verified efficacy and safety data.
Sales Analysis of Point-of-care Molecular Diagnostics Market in UK
Infrastructure investment in UK is supporting point-of-care molecular diagnostics demand at 9.8% through 2036. Growth is led by NHS procurement frameworks, MHRA regulatory pathways, and hospital modernization programs creating demand for assays and kits.
- Volume demand for assays and kits is led by hospital and clinic channels, reflecting respiratory diseases requirements and regulatory compliance standards in UK.
- Cancer and oncology assays adoption is supported by diagnostic and outpatient settings as clinical protocols evolve and physicians offices buyers expand supplier qualification programs.
- Respiratory diseases procurement is shifting toward clinical validation requirements and growing preference for regulatory-cleared assays and kits products with verified efficacy and safety data.
Competitive Landscape and Strategic Positioning
- Abbott Laboratories leads the point-of-care molecular diagnostics market through broad regulatory clearance portfolios, clinical evidence depth, and established hospital procurement relationships across Japan, USA, and EU.
- Cepheid (Danaher Corporation), bioMérieux SA, and Roche Diagnostics maintain competitive positions through specialized product lines in assays and kits and cancer and oncology assays categories.
- Emerging participants are targeting specialized clinical applications in respiratory diseases and sexually transmitted diseases segments to establish initial procurement relationships.
Abbott Laboratories leads the point-of-care molecular diagnostics market through broad regulatory clearance portfolios and clinical validation across FDA and EU MDR pathways. Cepheid (Danaher Corporation) maintains a strong position through specialized cancer and oncology assays product lines.
bioMérieux SA and Roche Diagnostics compete on product performance and institutional access. Barriers include regulatory timelines, clinical evidence, and GPO contracts.
Strategic priorities for market leaders include expanding assays and kits portfolios into sexually transmitted diseases applications, accelerating regulatory submissions in emerging markets, and reducing manufacturing cost per unit.
Key Companies in the Point-of-care Molecular Diagnostics Market
Key global companies leading the point-of-care molecular diagnostics market include:
- Abbott Laboratories, Cepheid (Danaher Corporation), bioMérieux SA, Roche Diagnostics, and QuidelOrtho Corporation maintain leading positions through established regulatory clearance portfolios, clinical evidence bases, and institutional procurement contracts across global markets.
- Regional competitors and mid-tier manufacturers compete through specialized cancer and oncology assays configurations, competitive pricing, and localized distribution networks in high-growth markets.
- Emerging entrants are targeting gastrointestinal disorders applications and point-of-care segments to establish initial procurement positions and scale.
Competitive Benchmarking: Point-of-care Molecular Diagnostics Market
| Company | Assays and Kits Range | Regulatory Coverage | Clinical Reach | Geographic Footprint |
|---|---|---|---|---|
| Abbott Laboratories | High | High | Strong | Global |
| Cepheid (Danaher Corporation) | High | High | Strong | Global |
| bioMérieux SA | Medium | High | Moderate | Regional |
| Roche Diagnostics | Medium | High | Moderate | Regional |
| QuidelOrtho Corporation | Medium | High | Moderate | Regional |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Point-of-care Molecular Diagnostics Market
- In 2025, Abbott Laboratories expanded its point-of-care molecular diagnostics portfolio by scaling manufacturing and broadening the availability of its ID NOW™ platform and associated molecular assays, including tests for Influenza A & B, RSV, and COVID-19, supporting rapid diagnostic workflows across hospitals, urgent care centers, and emergency departments in North America and Europe.
- In 2025, Cepheid (Danaher Corporation) expanded its molecular diagnostics portfolio on the GeneXpert® System by advancing oncology and infectious disease testing, including the Xpert® Xpress MVP assay for women’s health and the Xpert® NPM1 Mutation assay for acute myeloid leukemia monitoring, while strengthening compliance with European IVDR requirements and supporting automated cartridge-based testing in hospital laboratories.
Key Players in the Point-of-care Molecular Diagnostics Market
Major Global Players
- Abbott Laboratories
- Cepheid (Danaher Corporation)
- bioMérieux SA
- Roche Diagnostics
- QuidelOrtho Corporation
Emerging Players/Startups
- Visby Medical
- Sherlock Biosciences
- Mammoth Biosciences
- Biomeme
- Detect Inc.
- Scope Fluidics
Point-of-care Molecular Diagnostics Market - Research Methodology
| Method | Description |
|---|---|
| Primary Research | FMI analysts conducted interviews with device manufacturers, clinical procurement specialists, hospital supply chain managers, and end-use operators across Japan, USA, and EU to validate demand patterns and pricing structures for assays and kits and related product categories. |
| Desk Research | Combined clinical trial registries, regulatory approval databases, reimbursement data, and manufacturer disclosures to establish baseline parameters for point-of-care molecular diagnostics across product and technology segments. |
| Market Sizing & Forecasting | Bottom-up aggregation across Assays and Kits, Cancer and Oncology Assays, and Instruments and Analyzers product categories and Respiratory Diseases, Sexually Transmitted Diseases, and Hospital Acquired Infections applications, triangulated with top-down macro indicators and regional adoption curves. |
| Data Validation | Quarterly data are cross-validated with regulatory clearance volumes, hospital procurement records and manufacturer revenue disclosures for point-of-care molecular diagnostics products. |
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Market size by 2036 | USD 15.1 Bn |
| Growth rate | 10.0% CAGR (2026 to 2036) |
| Forecast period | 2026 to 2036 |
| Base year value (2025) | USD 5.3 Bn |
| Key Segment Covered | Product, Technology, Application, End Use, Sample Type, Deployment |
| Regions covered | North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries covered | USA, Japan, South Korea, UK, 30 plus countries |
| Key companies profiled | Abbott Laboratories, Cepheid (Danaher Corporation), bioMérieux SA, Roche Diagnostics, QuidelOrtho Corporation |
Market Segmentation Analysis
Point-of-care Molecular Diagnostics Market Segmented by Product:
- Assays and Kits
- Respiratory Disease Assays
- Influenza Testing Kits
- Coronavirus Detection Kits
- Sexually Transmitted Disease Assays
- Chlamydia Detection Kits
- Gonorrhea Detection Kits
- Hospital Acquired Infection Assays
- Methicillin Resistant Staphylococcus Aureus Kits
- Clostridioides Difficile Kits
- Respiratory Disease Assays
- Cancer and Oncology Assays
- Genetic Mutation Detection
- Tumor Marker Panels
- Instruments and Analyzers
- Portable Molecular Analyzers
- Handheld Devices
- Battery Operated Systems
- Bench Top Analyzers
- Multi Sample Systems
- High Throughput Platforms
- Integrated Systems
- Sample to Answer Platforms
- Cartridge Based Systems
- Portable Molecular Analyzers
- Software and Services
- Data Analysis Software
- Result Interpretation
- Reporting Systems
- Connectivity Solutions
- Laboratory Information Integration
- Cloud Based Platforms
- Service and Maintenance
- Technical Support
- System Upgrades
- Data Analysis Software
Point-of-care Molecular Diagnostics Market Segmented by Technology:
- Real Time Polymerase Chain Reaction
- Quantitative Polymerase Chain Reaction
- High Sensitivity Detection
- Rapid Amplification
- Multiplex Polymerase Chain Reaction
- Multi Pathogen Detection
- Panel Based Testing
- Quantitative Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification
- Loop Mediated Amplification
- Rapid Amplification
- Point of Care Use
- Recombinase Polymerase Amplification
- Low Temperature Amplification
- Portable Testing
- Loop Mediated Amplification
- Other Technologies
- Nucleic Acid Sequencing
- Targeted Sequencing
- Rapid Sequencing
- Microarray Technology
- Gene Expression Analysis
- Multiplex Detection
- Nucleic Acid Sequencing
Point-of-care Molecular Diagnostics Market Segmented by Application:
- Respiratory Diseases
- Upper Respiratory Infections
- Influenza
- Common Cold Pathogens
- Lower Respiratory Infections
- Pneumonia
- Tuberculosis
- Upper Respiratory Infections
- Sexually Transmitted Diseases
- Bacterial Infections
- Chlamydia
- Gonorrhea
- Viral Infections
- Human Immunodeficiency Virus
- Human Papillomavirus
- Bacterial Infections
- Hospital Acquired Infections
- Bacterial Infections
- Methicillin Resistant Staphylococcus Aureus
- Vancomycin Resistant Enterococci
- Clostridioides Difficile Infection
- Toxin Detection
- Rapid Screening
- Bacterial Infections
- Cancer
- Oncology Diagnostics
- Genetic Mutation Testing
- Biomarker Detection
- Personalized Medicine
- Companion Diagnostics
- Targeted Therapy Selection
- Oncology Diagnostics
- Hepatitis
- Hepatitis B
- Viral Load Testing
- Screening
- Hepatitis C
- Genotyping
- Monitoring
- Hepatitis B
- Gastrointestinal Disorders
- Bacterial Infections
- Salmonella
- Escherichia Coli
- Viral Infections
- Norovirus
- Rotavirus
- Bacterial Infections
Point-of-care Molecular Diagnostics Market Segmented by End Use:
- Physicians Offices
- Private Clinics
- Primary Care Clinics
- Specialty Clinics
- Diagnostic Centers
- Walk In Clinics
- Outpatient Testing
- Private Clinics
- Hospitals and Intensive Care Units
- Emergency Departments
- Rapid Diagnosis
- Critical Care Testing
- Inpatient Settings
- Routine Testing
- Infection Control
- Emergency Departments
- Research Institutes
- Academic Research
- Clinical Studies
- Molecular Research
- Clinical Research Organizations
- Trial Testing
- Biomarker Research
- Academic Research
- Other End Users
- Public Health Laboratories
- Disease Surveillance
- Outbreak Monitoring
- Home Care Settings
- Self Testing
- Remote Diagnostics
- Public Health Laboratories
Point-of-care Molecular Diagnostics Market Segmented by Sample Type:
- Blood Samples
- Whole Blood Testing
- Point of Care Testing
- Rapid Diagnostics
- Plasma and Serum Testing
- Laboratory Confirmation
- Advanced Testing
- Whole Blood Testing
- Swab Samples
- Nasal Swabs
- Respiratory Testing
- Viral Detection
- Throat Swabs
- Infection Screening
- Rapid Testing
- Nasal Swabs
- Urine Samples
- Routine Testing
- Sexually Transmitted Disease Testing
- Screening Programs
- Specialized Testing
- Hormone Detection
- Infection Monitoring
- Routine Testing
Point-of-care Molecular Diagnostics Market Segmented by Deployment:
- Portable Systems
- Handheld Devices
- Field Testing
- Remote Locations
- Compact Systems
- Clinic Based Testing
- Mobile Units
- Handheld Devices
- Near Patient Systems
- Bedside Testing
- Hospital Use
- Intensive Care Units
- Clinic Based Systems
- Primary Care Use
- Diagnostic Centers
- Bedside Testing
Point-of-care Molecular Diagnostics Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Türkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). WHO Global Report on Medical Device Access and Procurement Standards. WHO.
- 2. USA Food and Drug Administration. (2025). FDA Medical Device Classification and Clearance Database: Point-of-care molecular diagnostics Products. FDA.
- 3. European Medicines Agency. (2025). EMA Annual Report on Medical Device Regulation Under EU MDR. EMA.
- 4. International Medical Device Regulators Forum. (2025). IMDRF Guidance on Respiratory Diseases Device Classification. IMDRF.
- 5. Organisation for Economic Co-operation and Development. (2025). OECD Health Statistics: Respiratory Diseases Indicators. OECD.
This bibliography is provided for reader reference.
This Report Answers
- Estimating the size of the point-of-care molecular diagnostics market and revenue projections from 2026 to 2036.
- Segmentation by product, technology, application, end use, sample type, deployment.
- Insights across more than 30 regional and country-level markets.
- Analysis of Respiratory Diseases, and Sexually Transmitted Diseases demand drivers, procurement patterns, and adoption dynamics.
- Assessment of the competitive landscape including Abbott Laboratories, Cepheid (Danaher Corporation), and bioMérieux SA and other participants.
- Identification of growth opportunities across assays and kits and cancer and oncology assays segments.
- Evaluation of supply chain dynamics, real time polymerase chain reaction trends, and distribution channel structures.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
How big is the point-of-care molecular diagnostics market in 2026?
The global point-of-care molecular diagnostics market is estimated to be valued at USD 5.8 billion in 2026.
What will be the size of the point-of-care molecular diagnostics market in 2036?
The market size for the point-of-care molecular diagnostics market is projected to reach USD 15.1 billion by 2036.
How much will the point-of-care molecular diagnostics market grow between 2026 and 2036?
The point-of-care molecular diagnostics market is expected to grow at a 10.0% CAGR between 2026 and 2036.
What are the key products in the point-of-care molecular diagnostics market?
The key products in the point-of-care molecular diagnostics market are Assays and Kits, Cancer and Oncology Assays, Instruments and Analyzers and Software and Services.
Which technology segment is expected to contribute a significant share in the point-of-care molecular diagnostics market in 2026?
In terms of technology, the real time polymerase chain reaction segment is expected to command 64.2% share in the point-of-care molecular diagnostics market in 2026.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Key Takeaways
- Market Size and CAGR
- Top Growth Driver
- Fastest Growing Segment
- Leading Region
- Key Companies
- Emerging Opportunities
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Analyst Perspective (What is happening? Why now? What should investors know?)
- Key Questions Answered
- How large is the market?
- What is the CAGR?
- What are key trends?
- Which region dominates?
- Who are the leaders?
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Expert Input and Fieldwork (Primary Evidence)
- Tooling, Models, and Reference Databases
- Data Engineering and Model Build
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics (Drivers, Restraints, Opportunity, Trends)
- Scenario Forecast (Optimistic, Likely, Conservative)
- Impact Analysis
- AI Impact
- Sustainability Impact
- Regulatory Impact
- Technology Impact
- Consumer / Buyer Analysis
- Purchase Drivers
- Adoption Barriers
- Buyer Journey
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter's Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Global Market Analysis and Forecast, 2021 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis, 2021 to 2036
- Global Market Analysis and Forecast, By Product, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Product, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Product, 2026 to 2036
- Assays and Kits
- Respiratory Disease Assays
- Sexually Transmitted Disease Assays
- Hospital Acquired Infection Assays
- Cancer and Oncology Assays
- Genetic Mutation Detection
- Tumor Marker Panels
- Instruments and Analyzers
- Portable Molecular Analyzers
- Bench Top Analyzers
- Software and Services
- Data Analysis Software
- Connectivity Solutions
- Assays and Kits
- Y-o-Y Growth Trend Analysis By Product, 2021 to 2025
- Absolute $ Opportunity Analysis By Product, 2026 to 2036
- Global Market Analysis and Forecast, By Technology, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Real Time Polymerase Chain Reaction
- Quantitative Polymerase Chain Reaction
- Multiplex Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification
- Loop Mediated Amplification
- Recombinase Polymerase Amplification
- Other Technologies
- Nucleic Acid Sequencing
- Microarray Technology
- Real Time Polymerase Chain Reaction
- Y-o-Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis and Forecast, By Application, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
- Respiratory Diseases
- Upper Respiratory Infections
- Lower Respiratory Infections
- Sexually Transmitted Diseases
- Bacterial Infections
- Viral Infections
- Hospital Acquired Infections
- Bacterial Infections
- Clostridioides Difficile Infection
- Cancer
- Oncology Diagnostics
- Personalized Medicine
- Hepatitis
- Hepatitis B
- Hepatitis C
- Gastrointestinal Disorders
- Bacterial Infections
- Viral Infections
- Respiratory Diseases
- Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
- Absolute $ Opportunity Analysis By Application, 2026 to 2036
- Global Market Analysis and Forecast, By End Use, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End Use, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2026 to 2036
- Physicians Offices
- Private Clinics
- Diagnostic Centers
- Hospitals and Intensive Care Value (USD Million)s
- Emergency Departments
- Inpatient Settings
- Research Institutes
- Academic Research
- Clinical Research Organizations
- Other End Users
- Public Health Laboratories
- Home Care Settings
- Physicians Offices
- Y-o-Y Growth Trend Analysis By End Use, 2021 to 2025
- Absolute $ Opportunity Analysis By End Use, 2026 to 2036
- Global Market Analysis and Forecast, By Sample Type, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Sample Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Sample Type, 2026 to 2036
- Blood Samples
- Whole Blood Testing
- Plasma and Serum Testing
- Swab Samples
- Nasal Swabs
- Throat Swabs
- Urine Samples
- Routine Testing
- Specialized Testing
- Blood Samples
- Y-o-Y Growth Trend Analysis By Sample Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Sample Type, 2026 to 2036
- Global Market Analysis and Forecast, By Deployment
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Deployment, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Deployment, 2026 to 2036
- Portable Systems
- Handheld Devices
- Compact Systems
- Near Patient Systems
- Bedside Testing
- Clinic Based Systems
- Portable Systems
- Y-o-Y Growth Trend Analysis By Deployment, 2021 to 2025
- Absolute $ Opportunity Analysis By Deployment, 2026 to 2036
- Global Market Analysis and Forecast, By Region, 2021 to 2036
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis and Forecast, By Country, 2021 to 2036
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- Latin America Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- Western Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- Eastern Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- East Asia Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- South Asia and Pacific Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- Middle East & Africa Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Türkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Türkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Product
- By Technology
- By Application
- By End Use
- By Sample Type
- By Deployment
- Emerging Startups
- Innovation Benchmarking
- Competition Analysis
- Competition Deep Dive
- Abbott Laboratories
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Region/Sales Channel)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Cepheid (Danaher Corporation)
- bioMérieux SA
- Roche Diagnostics
- QuidelOrtho Corporation
- Other Companies (combined)
- Abbott Laboratories
- Case Studies
- Success Stories
- Recent Developments
- Competition Deep Dive
- Assumptions & Acronyms Used
